Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma

Wen Lun Wang, Wei-Lun Chang, Hsiao Bai Yang, Yu Chi Wang, I. Wei Chang, Ching Tai Lee, Chi Yang Chang, Jaw Town Lin, Bor-Shyang Sheu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with esophageal squamous cell carcinomas (ESCCs) have poor survival and high recurrence rate, but lack a prognostic biomarker. Disabled-2 (DAB2) is a crucial tumor suppressor, but its roles in ESCCs are uncertain. We investigated whether low DAB2 expression in ESCCs could lead into tumor progression and poor prognosis. Our results found patients with low-DAB2 expression ESCCs had significantly larger tumor size, deeper tumor invasion depth, lymph node metastasis, worse survival, and higher recurrence rate (P<0.05). The Cox-regression model revealed low-DAB2 expression was an independent factor of poor survival (P<0.05), and also of tumor recurrence with the predictive performance superior to clinical TNM stage (P<0.05). Low-DAB2 cancer cells, validated by DAB2 knockdown or overexpression, had higher phosphorylated ERK and migration abilities, which could be suppressed by ERK inhibitor treatment. TGF-β-induced epithelial-to-mesenchymal transition (EMT) only existed in the high-DAB2 cells, and related to worse prognosis of high-DAB2 ESCCs (P<0.05). In conclusion, DAB2 can suppress the ERK signaling, but correlate to have TGF-β-induced EMT in ESCCs. DAB2 expression could be a biomarker to identify patients with worse survival and high recurrence. Our data suggest DAB2 expression can stratify patients in need of aggressive surveillance and with possible benefit from anti-ERK or anti-TGF-β therapies.

Original languageEnglish
Pages (from-to)71169-71181
Number of pages13
JournalOncotarget
Volume7
Issue number44
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Recurrence
Survival
Neoplasms
Epithelial-Mesenchymal Transition
Biomarkers
Proportional Hazards Models
Esophageal Squamous Cell Carcinoma
Lymph Nodes
Neoplasm Metastasis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Wang, Wen Lun ; Chang, Wei-Lun ; Yang, Hsiao Bai ; Wang, Yu Chi ; Chang, I. Wei ; Lee, Ching Tai ; Chang, Chi Yang ; Lin, Jaw Town ; Sheu, Bor-Shyang. / Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 44. pp. 71169-71181.
@article{1344b5df88a94318b62d59b91e3aa314,
title = "Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma",
abstract = "Patients with esophageal squamous cell carcinomas (ESCCs) have poor survival and high recurrence rate, but lack a prognostic biomarker. Disabled-2 (DAB2) is a crucial tumor suppressor, but its roles in ESCCs are uncertain. We investigated whether low DAB2 expression in ESCCs could lead into tumor progression and poor prognosis. Our results found patients with low-DAB2 expression ESCCs had significantly larger tumor size, deeper tumor invasion depth, lymph node metastasis, worse survival, and higher recurrence rate (P<0.05). The Cox-regression model revealed low-DAB2 expression was an independent factor of poor survival (P<0.05), and also of tumor recurrence with the predictive performance superior to clinical TNM stage (P<0.05). Low-DAB2 cancer cells, validated by DAB2 knockdown or overexpression, had higher phosphorylated ERK and migration abilities, which could be suppressed by ERK inhibitor treatment. TGF-β-induced epithelial-to-mesenchymal transition (EMT) only existed in the high-DAB2 cells, and related to worse prognosis of high-DAB2 ESCCs (P<0.05). In conclusion, DAB2 can suppress the ERK signaling, but correlate to have TGF-β-induced EMT in ESCCs. DAB2 expression could be a biomarker to identify patients with worse survival and high recurrence. Our data suggest DAB2 expression can stratify patients in need of aggressive surveillance and with possible benefit from anti-ERK or anti-TGF-β therapies.",
author = "Wang, {Wen Lun} and Wei-Lun Chang and Yang, {Hsiao Bai} and Wang, {Yu Chi} and Chang, {I. Wei} and Lee, {Ching Tai} and Chang, {Chi Yang} and Lin, {Jaw Town} and Bor-Shyang Sheu",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.8460",
language = "English",
volume = "7",
pages = "71169--71181",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "44",

}

Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma. / Wang, Wen Lun; Chang, Wei-Lun; Yang, Hsiao Bai; Wang, Yu Chi; Chang, I. Wei; Lee, Ching Tai; Chang, Chi Yang; Lin, Jaw Town; Sheu, Bor-Shyang.

In: Oncotarget, Vol. 7, No. 44, 01.01.2016, p. 71169-71181.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma

AU - Wang, Wen Lun

AU - Chang, Wei-Lun

AU - Yang, Hsiao Bai

AU - Wang, Yu Chi

AU - Chang, I. Wei

AU - Lee, Ching Tai

AU - Chang, Chi Yang

AU - Lin, Jaw Town

AU - Sheu, Bor-Shyang

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients with esophageal squamous cell carcinomas (ESCCs) have poor survival and high recurrence rate, but lack a prognostic biomarker. Disabled-2 (DAB2) is a crucial tumor suppressor, but its roles in ESCCs are uncertain. We investigated whether low DAB2 expression in ESCCs could lead into tumor progression and poor prognosis. Our results found patients with low-DAB2 expression ESCCs had significantly larger tumor size, deeper tumor invasion depth, lymph node metastasis, worse survival, and higher recurrence rate (P<0.05). The Cox-regression model revealed low-DAB2 expression was an independent factor of poor survival (P<0.05), and also of tumor recurrence with the predictive performance superior to clinical TNM stage (P<0.05). Low-DAB2 cancer cells, validated by DAB2 knockdown or overexpression, had higher phosphorylated ERK and migration abilities, which could be suppressed by ERK inhibitor treatment. TGF-β-induced epithelial-to-mesenchymal transition (EMT) only existed in the high-DAB2 cells, and related to worse prognosis of high-DAB2 ESCCs (P<0.05). In conclusion, DAB2 can suppress the ERK signaling, but correlate to have TGF-β-induced EMT in ESCCs. DAB2 expression could be a biomarker to identify patients with worse survival and high recurrence. Our data suggest DAB2 expression can stratify patients in need of aggressive surveillance and with possible benefit from anti-ERK or anti-TGF-β therapies.

AB - Patients with esophageal squamous cell carcinomas (ESCCs) have poor survival and high recurrence rate, but lack a prognostic biomarker. Disabled-2 (DAB2) is a crucial tumor suppressor, but its roles in ESCCs are uncertain. We investigated whether low DAB2 expression in ESCCs could lead into tumor progression and poor prognosis. Our results found patients with low-DAB2 expression ESCCs had significantly larger tumor size, deeper tumor invasion depth, lymph node metastasis, worse survival, and higher recurrence rate (P<0.05). The Cox-regression model revealed low-DAB2 expression was an independent factor of poor survival (P<0.05), and also of tumor recurrence with the predictive performance superior to clinical TNM stage (P<0.05). Low-DAB2 cancer cells, validated by DAB2 knockdown or overexpression, had higher phosphorylated ERK and migration abilities, which could be suppressed by ERK inhibitor treatment. TGF-β-induced epithelial-to-mesenchymal transition (EMT) only existed in the high-DAB2 cells, and related to worse prognosis of high-DAB2 ESCCs (P<0.05). In conclusion, DAB2 can suppress the ERK signaling, but correlate to have TGF-β-induced EMT in ESCCs. DAB2 expression could be a biomarker to identify patients with worse survival and high recurrence. Our data suggest DAB2 expression can stratify patients in need of aggressive surveillance and with possible benefit from anti-ERK or anti-TGF-β therapies.

UR - http://www.scopus.com/inward/record.url?scp=84995428222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995428222&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8460

DO - 10.18632/oncotarget.8460

M3 - Article

C2 - 27036032

AN - SCOPUS:84995428222

VL - 7

SP - 71169

EP - 71181

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -